Chiltern International and Charles River Laboratories have entered into a collaboration under which Chiltern Early Phase will partner with Charles River to conduct and support radiolabelled studies.

Glenn Kerkhof, Chiltern’s chief executive officer, stated, “This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Chiltern Early Phase in Dundee, Scotland will perform the clinical aspects of the radiolabelled studies. These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”

Chiltern Early Phase has a dedicated 42-bed clinical pharmacology unit located in a UK National Health Service hospital and leading medical school. In addition, Chiltern Early Phase offers an extensive database of healthy volunteers and other patient populations.

The Metabolism and Pharmacokinetics group at Charles River, Edinburgh, has been conducting radiolabelled trials in man for more than 20 years. The facility includes a GMP clean room, licensed for the manufacture of radiolabelled drug products, including aseptic products for parenteral use. According to CRL, the close proximity of the laboratories allows for quick turnaround (within 24 hours) of radioactivity data.